Findings

What do systematic reviews say?

584 questions · 590 findings · 240 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 106 · 18%GRADE not reported 94 · 15.9%Very low 137 · 23.2%Low 134 · 22.7%Moderate 98 · 16.6%High 21 · 3.6%

Inactivated influenza vaccine vs placebo

Asthma exacerbation (adverse effects) caused by inactivated influenza vaccine, measured in the first 2 weeks following vaccination ‐ children (over 3 years of age) given inactivated influenza vaccine · people with asthma

1 finding from 1 review

Vaccines for preventing influenza in people with asthma 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 712 participants
Moderate

Brexpiprazole vs antidepressive agents

Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 2.88 [1.37, 6.05]
6 studies · 2472 participants
High

Brexpiprazole vs antidepressive agents

Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 2.95 [2.06, 4.21]
7 studies · 3358 participants
Moderate

Brexpiprazole vs antidepressive agents

Weight gain · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 3.14 [2.19, 4.49]
9 studies · 3424 participants
Moderate